First Line Anti-Tubercular Drug Resistance Pattern of Mycobacterium Tuberculosis Isolated From Specialized Hospitals of Dhaka City

M. Mohiuddin, J. Haq
{"title":"First Line Anti-Tubercular Drug Resistance Pattern of Mycobacterium Tuberculosis Isolated From Specialized Hospitals of Dhaka City","authors":"M. Mohiuddin, J. Haq","doi":"10.3329/IMCJ.V8I2.26677","DOIUrl":null,"url":null,"abstract":"The present study was undertaken to determine the drug resistance pattern of M. tuberculosis isolated from 225 pulmonary and 45 extrapulmonary tuberculosis cases. The samples were cultured on Lowenstein Jensen (L-J) media for isolation of M. tuberculosis . Drug resistance to first line anti tubercular drugsnamely isoniazid (INH), rifampicin (RIF), Ethambutol (ETH) and streptomycin (SM) were determined by indirect proportion method. The overall drug resistance of M. tuberculosis was 53.6% to any of the first line anti tubercular drugs. Rate of multi drug resistant tuberculosis (MDR-TB) among the untreated cases was 4.2%, while it was 36.0% in previously treated cases. It was found that 83.3% rifampicin resistant M. tuberculosis was cross resistant to one or more of other first line anti-tubercular drugs, while cross resistance of INH, ETH and SM resistant isolates was much low. The present study revealed that high level of drug resistance exists to individual anti tubercular drugs and MDR-TB is an emerging problem, particularly in treated cases. Rifampicin resistance could be used as a surrogate marker for drug resistance to other first line anti tubercular drugs. Ibrahim Med. Coll. J. 2014; 8(2): 41-46","PeriodicalId":226732,"journal":{"name":"Ibrahim Medical College Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ibrahim Medical College Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3329/IMCJ.V8I2.26677","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

The present study was undertaken to determine the drug resistance pattern of M. tuberculosis isolated from 225 pulmonary and 45 extrapulmonary tuberculosis cases. The samples were cultured on Lowenstein Jensen (L-J) media for isolation of M. tuberculosis . Drug resistance to first line anti tubercular drugsnamely isoniazid (INH), rifampicin (RIF), Ethambutol (ETH) and streptomycin (SM) were determined by indirect proportion method. The overall drug resistance of M. tuberculosis was 53.6% to any of the first line anti tubercular drugs. Rate of multi drug resistant tuberculosis (MDR-TB) among the untreated cases was 4.2%, while it was 36.0% in previously treated cases. It was found that 83.3% rifampicin resistant M. tuberculosis was cross resistant to one or more of other first line anti-tubercular drugs, while cross resistance of INH, ETH and SM resistant isolates was much low. The present study revealed that high level of drug resistance exists to individual anti tubercular drugs and MDR-TB is an emerging problem, particularly in treated cases. Rifampicin resistance could be used as a surrogate marker for drug resistance to other first line anti tubercular drugs. Ibrahim Med. Coll. J. 2014; 8(2): 41-46
达卡市专科医院分离结核分枝杆菌一线耐药模式分析
本研究对225例肺结核和45例肺外结核分离的结核分枝杆菌的耐药模式进行了研究。样品在Lowenstein Jensen (L-J)培养基上培养,分离结核分枝杆菌。采用间接比例法测定一线抗结核药物异烟肼(INH)、利福平(RIF)、乙胺丁醇(ETH)和链霉素(SM)的耐药性。结核分枝杆菌对一线抗结核药物的总体耐药率为53.6%。在未经治疗的病例中,耐多药结核病(MDR-TB)的发病率为4.2%,而在曾经接受治疗的病例中,这一比例为36.0%。结果显示,83.3%的耐利福平结核分枝杆菌对一线抗结核药物交叉耐药,而INH、ETH和SM耐药株交叉耐药率较低。目前的研究表明,对个别抗结核药物存在高度耐药性,耐多药结核病是一个新出现的问题,特别是在治疗病例中。利福平耐药可作为其他一线抗结核药物耐药的替代指标。易卜拉欣·迈德,上校。j . 2014;8 (2): 41-46
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信